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Will Social Values Influence the Development 
of HMOs? 
JOHN B. DAVIS 
Among industrialized nations the 
United States is relatively unique in 
relying on a mix of public and private 
financing and delivery of healthcare: 
federal and federal-state programs, 
such as Medicare and Medicaid; 
employment-based health insurance 
(primarily HMOs); and state-subsidized 
insurance pools for high-risk individ-
uals. In recent years, however, there 
have been efforts to apply the princi-
ples of private employment-based 
health insurance to the other forms of 
healthcare, and there is speculation that 
rising healthcare costs can only be 
addressed by further extending capi-
tated payment plans. This suggests that 
U.S. healthcare may increasingly be 
organized according to market princi-
ples. For some, this represents a his-
toric departure from an emphasis on 
public responsibility for healthcare and 
a sacrifice of the value principles 
embodied in health relationships 
between patient and provider. But 
defenders of HMOs and a larger role 
for markets argue that managed care 
allows for a more rational allocation 
of scarce healthcare resources by min-
imizing inefficient low-benefit-high-
cost care. More individuals receive 
essential care if inessential care is elim-
inated. HMOs are also said to encour-
age non-HMOs to provide lower priced 
healthcare. 
Interestingly, recent evidence sug-
gests that HMO market share will not 
continue to expand through price and 
cost competition but only if HMOs 
address quality of care-in market 
terms, a process understood by econ-
omists as product differentiation. But 
there is a complication. Unlike other 
types of consumption, healthcare is 
consumed in "bundles" whose compo-
sition depends on a shared decision-
making process between patients and 
healthcare providers. This decisionrnak-
ing exhibits nonrnarket values that may 
constitute a barrier to the extension of 
market principles through product dif-
ferentiation. Here, I look at these eco-
nomic and social value issues to 
consider how healthcare delivery may 
evolve in the United States in the 
future . 
HMO Expansion: Experience and 
Prospects 
HMOs have increased market share 
by cost-containment strategies involv-
ing physician oversight and incentive 
adjustment, fewer and shorter hospi-
talization stays, and fewer and less 
diagnostic testing. 1 Their success at 
cost containment is due in large part 
to selection bias in enrolling healthier-
than-average patients previously 
enrolled in traditional plans. To com-
pete, non-HMOs have also had to 
charge lower premiums, despite being 
left with less healthier-than-average, 
more costly patients. Together this 
should imply lower average premi-
ums across HMO and non-HMOs. 
There is evidence, however, that where 
HMOs have achieved large market 
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share average premiums are higher.2 
Why? 
Baker and Corts ask whether non-
HMO premiums fall when HMO mar-
ket share is low due to competitive 
pressures, and then rise when HMO 
market share rises due to changing 
patient pools.3 They find that non-
HMO premiums fall until HMO mar-
ket share is about 15 percent, and rise 
thereafter. But as HMO shares rise, 
HMOs also cease lowering premiums 
because there are fewer healthy patients 
to draw from non-HMO plans. This 
reinforces the rise in average premi-
ums. Thus average premiums are 
higher, and HMOs have also lost their 
primary means of expanding market 
share. Further HMO expansion, then, 
either requires new markets with little 
HMO development or that HMOs 
adopt new strategies of expansion. 
Other factors support the conclu-
sion that HMOs are done lowering 
premiums. With less price competi-
tion from traditional insurers, HMOs 
may choose to "shadow price" tradi-
tional insurers by charging premiums 
just below the latter's, irrespective of 
HMO costS.4 If market entry and the 
acquisition of market share involves 
significant overhead costs, HMOs may 
attempt to recover initial investment 
costs when the pressure to maintain 
low premiums abates. Further, if mar-
kets are dominated by a small number 
of HMOs, premiums may simply rise 
with oligopoly pricing. 
This overall picture is consistent with 
the emergence of a "mature" market 
in which a set of technical and orga-
nizational advantages is realized by 
innovative firms that displace less inno-
vative firms. Having realized the 
advantages of organizational restruc-
turing and patient sorting, HMOs now 
seem to need new ways to expand. 
Historically, firms in other "mature" 
industries have tried to differentiate 
their products to increase sales and 
gain additional market share. Evi-
dence that HMOs have begun to adopt 
this strategy exists in the advertising 
in which HMOs now regularly engage. 
Values in Healthcare versus Values 
in the Market 
Healthcare may be represented as a bun-
dle of different goods and services con-
sumed to produce health, where 
individuals demand healthcare goods 
and services as inputs to a production 
process whose output is their own 
health.5 This relationship is compli-
cated by three factors: (1) health pos-
sesses many dimensions -physical, 
psychological, and social-whose rela-
tionships are often not well understood; 
(2) information about the ways in which 
health can be produced is extensive and 
complex, making consumers depen-
dent on healthcare providers; and (3) 
individuals often wish to delegate much 
of their responsibility for decisionmak-
ing to family members and healthcare 
providers, because their health states can 
change over the period of their inter-
action with healthcare providers. 
One way of thinking about this is to 
focus on how patients and providers 
trea t healthcare decisionmaking as a 
shared decisionmaking process.6 
Because individuals are often unclear 
about what health states they wish to 
produce, unclear about how to best 
make use of healthcare, and unwilling 
to be fully responsible for needed deci-
sionmaking, they invite healthcare pro-
viders' participation in a shared 
decisionmaking process. From this per-
spective, point (1) suggests that indi-
viduals rely on healthcare providers 
to help them evaluate possible health 
state outcomes, given that they typi-
cally have less understanding than pro-
viders do of the likely nature of 
different health state outcomes. Point 
(2) suggests that, because medical sci-
ence only predicts probable outcomes, 
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providers must be able to explain pos-
sibilities and tradeoffs between health 
states associated with different medi-
cal interventions, thus "framing" indi-
viduals' evaluation of health state 
outcomes. Finally, because, according 
to point (3), individuals may not always 
make clear choices regarding health-
care, determination of health out-
comes again devolves partly on 
providers who attempt to make health-
care decisions that they believe to be 
in the best interest of the individual. 
Emphasizing the shared character 
of healthcare decisionmaking draws 
our attention to an interaction between 
individuals that differs from the kind 
of interaction that occurs between indi-
viduals engaged in market exchange. 
Suppose we think of values in the 
most general sense as appraisals of 
worth. In the case of market inter-
action, individuals' appraisals of worth 
are usually taken to be their prefer-
ences. According to the usual view of 
market exchange, values thus under-
stood are "external" to individuals' 
interaction in market exchange. Mar-
ket participants need only know what 
goods are offered or demanded and at 
what prices to transact with one an-
other. Market exchange of goods and 
services makes communication regard-
ing values unnecessary, thus isolating 
individuals from one another in value 
terms. Nor, according to standard eco-
nomic theory, are individuals' values 
altered or influenced by their market 
interaction with one another. In con-
trast, with healthcare decisionmaking 
understood as a shared process, indi-
viduals and providers jointly appraise 
the worth of possible health out-
comes. Their values cannot remain 
"external" to their interaction, because 
each must reflect on what the other 
values to establish which health out-
comes will be pursued. 
The bundling of healthcare inputs 
under shared decisionmaking, then, 
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involves a role for values different from 
the role they take on in the market 
process. Indeed, there is a special field 
of investigation specifically devoted 
to this distinct realm of values and the 
decisionmaking concerned. Bioethics, 
or the ethics of healthcare, investi-
gates healthcare values and how to 
resolve value conflicts encountered in 
making choices about how to bundle 
healthcare goods and services. As an 
area of applied ethics, bioethics stud-
ies the integration of the ethics of med-
icine and broad moral theories of well-
being and individual righ~. More 
concretely, bioethics studies how indi-
viduals and providers reach agree-
ment regarding desirable health 
outcomes. The moral theory context in 
which this process is explained reflects 
the fact that shared decisionmaking 
over healthcare inescapably brings up 
such matters as the nature of the good 
life, the meaning of well-being, patient 
and provider rights, personal dignity, 
and so on. In economics, in contrast, 
because the logic of the marketplace 
explains individuals' interaction, moral 
theory is left out the picture entirely, 
and the only way values can be dis-
cussed is as individuals' private 
preferences. 
HMO Expansion and Conflict 
Between Market and Nonmarket 
Values 
Product differentiation occurs when 
firms distinguish their own goods from 
those of other firms to attract consum-
ers. Some differences are cosmetic, 
whereas others alter the nature of the 
good or add new features . The impor-
tance of this to HMOs seeking market-
share expansion lies in the relative 
ease of each type of differentiation. 
Cosmetic changes, such as in market-
ing, business support staff tasks, and 
other matters incidental to the actual 
delivery of healthcare, can usually be 
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made unilaterally by HMOs. How-
ever, changes in the nature of health-
care affecting the relationship between 
individuals and providers cannot be 
made without their participation. It is 
this latter sort of change, however, 
that is ultimately most important if 
HMOs are to differentiate themselves 
in terms of quality of care. 
Factor into this that past changes in 
HMO healthcare plans associated with 
cost-containment strategies (reduced 
hospital stays, less diagnostic work-
up, etc.) have been regarded by some 
as a stripping-down process. Although 
surveys show that consumers have 
been largely satisfied with HMOs, they 
also show concerns regarding quality 
of care. The task for HMOs, then, is to 
defend cost-containment strategies and 
also deliver what is perceived as qual-
ity care, where quality is determined 
by individual-provider shared decision-
making. Consider the controversy over 
mothers' length of hospital stay after 
giving birth. Individuals and provid-
ers have been outspoken in criticizing 
HMOs' short hospital stay policies as 
harmful to the health of mothers and 
infants. HMOs have thus had to scale 
back cost guidelines or offer outpa-
tient care seen to be of comparable 
quality. Because both options add to 
costs, neither has been adopted with-
out pressure. In this instance, then, 
quality-enhancing product differentia-
tion has not only required backtrack-
ing on cost-containment strategies but 
also a shift in control away from HMO 
managers. 
Will HMOs, then, continue to expand 
by emphasizing quality of care? My 
view is that they may but that this 
may require introducing a significant 
role for nonmarket values. On the one 
hand, product differentiation could 
raise HMO sales and revenue by as 
much or more as it increases costs; 
thus profits-the HMO measure of 
health-need not fall and might even 
rise. In effect, the increased extent of 
the market could compensate for the 
higher per-person cost of care. But on 
the other hand, because this develop-
ment would seem to involve an 
expanded role for individual-provider 
decisionmaking, it would enlarge the 
place of nonmarket values in HMO 
healthcare delivery. Ironically, then, 
whereas other expansions of the mar-
ket into social domains previously not 
organized along market lines have been 
labeled "imperialistic" on account of 
the incursion of market values into 
nonmarket value domains, in this 
instance the reverse seems quite pos-
sible. The further expansion of HMOs 
may rather require significant compro-
mise in market principles. Should this 
indeed be the case, the reason that 
nonmarket values might have this role 
would seem to come down to the atyp-
ical nature of healthcare as a commod-
ity: its delivery and provision depends 
on a shared decisionmaking process 
between individual and provider-a 
relationship that makes value "inter-
nal" to exchange rather than "exter-
nal" as in most other kinds of markets. 
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